Medicine and Dentistry
Botulinum Toxin A
100%
Overactive Bladder
56%
Intermittent Catheterisation
50%
Predictive Factor
50%
Retrospective Cohort Study
50%
Lidocaine
50%
Placebo
37%
Visual Analog Scale
18%
Urodynamics
15%
Bladder
15%
Table Salt
12%
Procedural Pain
12%
Patient Satisfaction
12%
Urine Incontinence
10%
Enuresis
10%
Multivariate Logistic Regression Analysis
10%
Bladder Capacity
10%
Anterior Colporrhaphy
10%
Residual Urine
6%
Catheterization
6%
Sodium Bicarbonate
6%
Outpatient
6%
Adverse Event
6%
Urinary Tract Infection
6%
Urogynecology
6%
Intravesical Drug Administration
6%
Adverse Effect
6%
Microhematuria
6%
Detrusor
5%
Protective Factor
5%
Incontinence
5%
Electronic Patient Record
5%
Promethazine
5%
Keyphrases
Predictive Factors
50%
OnabotulinumtoxinA Injection
50%
Clean Intermittent Catheterization
50%
Intravesical
50%
Retrospective Cohort Study
50%
Overactive Bladder Symptom Score (OABSS)
50%
Alkalinized Lidocaine
50%
Botulinum Neurotoxin (BoNT)
25%
Bladder Diary
15%
Urodynamic Study
15%
Bladder Volume
10%
Logistic Regression Analysis
10%
Urgency Urinary Incontinence
10%
Anterior Colporrhaphy
10%
Sodium Hydrogen Carbonate
7%
Intradetrusor onabotulinumtoxinA
7%
Anesthetic Treatment
7%
Demographic History
5%
Post-void Residual
5%
Univariate Logistic Regression
5%
Incontinence
5%
Decreased Risk
5%
International Units
5%
Statistical Analysis
5%
Objective Examination
5%
Medical History
5%
OnabotulinumtoxinA
5%
Botox
5%
Protective Factors
5%
Maximum Cystometric Capacity
5%
Diary Study
5%
Retrospective Cohort
5%
Electronic Medical Records
5%
Gynecological History
5%
Detrusor
5%
Risk Factors
5%
Pharmacology, Toxicology and Pharmaceutical Science
Botulinum Toxin A
50%
Lidocaine
50%
Placebo
37%
Procedural Pain
12%
Table Salt
12%
Residual Urine
6%
Overactive Bladder
6%
Adverse Event
6%
Urinary Tract Infection
6%
Dicarbonate
6%
